IP Library › Granted Patent US 11,279,746
Granted Patent B2
US 11,279,746 · App. 16/803,230 · Granted Mar 22, 2022

ALK4:ActRIIB heteromultimers and uses thereof

Inventors: Ravindra Kumar (Acton, MA); Asya Grinberg (Lexington, MA); Dianne Sako (Medford, MA); Robert Scott Pearsall (North Reading, MA); Roselyne Castonguay (Watertown, MA)
Assignee: ACCELERON PHARMA INC.
C07K14/705C07K14/71C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,279,746
App. No.
16/803,230
Granted
Mar 22, 2022
Kind
B2
Abstract

In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

Claims (21)

1. An isolated nucleic acid sequence comprising:

a) a nucleotide sequence encoding an ALK4 polypeptide, wherein the nucleotide sequence is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43, and

b) a nucleotide sequence encoding an ActRIIB polypeptide, wherein the nucleotide sequence is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40.

2. A recombinant polynucleotide comprising a promoter sequence operably linked to a nucleotide sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43 and a nucleotide sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40.

3. A vector comprising the recombinant polynucleotide of claim 2 .

4. A cell transformed with the recombinant polynucleotide of claim 2 .

5. The cell of claim 4 , wherein the cell is a CHO cell.

6. A method of making a heteromultimer comprising an ALK4 polypeptide and an ActRIIB polypeptide comprising:

a) culturing a cell under conditions suitable for expression of an ALK4 polypeptide and an ActRIIB polypeptide, wherein the cell comprises the recombinant polynucleotide of claim 2 ; and

b) recovering the heteromultimer so expressed.

7. The method of claim 6 , wherein the ALK4 polypeptide or ActRIIB polypeptide is expressed using a TPA leader sequence.

8. The method of claim 7 , wherein the TPA leader comprises of SEQ ID NO: 38.

9. The method of claim 6 , wherein the cell is a CHO cell.

10. The method of claim 6 , wherein the heteromultimer is a heterodimer.

11. A method of making a heteromultimer comprising an ALK4 polypeptide and an ActRIIB polypeptide comprising:

a) culturing a first cell under conditions suitable for expression of an ALK4 polypeptide, wherein the first cell comprises a recombinant polynucleotide comprising a promoter sequence operably linked to a nucleotide sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43;

b) recovering the ALK4 polypeptide so expressed;

c) culturing a second cell under conditions suitable for expression of an ActRIIB polypeptide, wherein the second cell comprises a recombinant polynucleotide comprising a promoter sequence operably linked to a nucleotide sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40;

d) recovering the ActRIIB polypeptide so expressed;

e) combining the recovered ALK4 polypeptide and the recovered ActRIIB polypeptide under conditions suitable for ALK4:ActRIIB heteromultimer formation; and

f) recovering the ALK4:ActRIIB heteromultimer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2020
From: KUMAR, RAVINDRA; GRINBERG, ASYA; SAKO, DIANNE; PEARSALL, ROBERT SCOTT; CASTONGUAY, ROSELYNE
To: ACCELERON PHARMA INC.
Reel/Frame 054269/0171 →
Continuity (5)
Continuation 16158661 · Oct 12, 2018
Division 15092573 · Apr 6, 2016
Provisional Application 62220836 · Sep 18, 2015
Provisional Application 62143579 · Apr 6, 2015
Related Publication 20210163569A1 · Jun 3, 2021
Cited By (1)
US 12,421,295